Celsion's Formulated DNA Plasmid COVID-19 Vaccine Candidate Shows Activity Against Two Strains
Celsion Corporation (NASDAQ:CLSN) has presented its PLACCINE platform technology at the World Vaccine Congress. "PLACCINE is demonstrating the potential to be a powerful platform that provides for rapid design capability for targeting two or more different variants of a single virus in one vaccine," said Dr. Khursheed Anwer, Chief Science Officer at Celsion.…
Benzinga ·
Benzinga
